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ABSTRACT  
Background: Type 2 diabetes mellitus (T2DM) is a major public health problem worldwide. 
Hypertension and inflammation are well recognized as risk factors for the macrovascular compli-
cations of diabetes. The aim of this study was to assess the impact of vitamin E supplementation 
on blood pressure (BP), serum high-sensitivity C-reactive protein (hs-CRP) and fasting blood 
glucose in patients with T2DM.  
Methods: In a double blind, randomized, controlled clinical trial, 83 patients with T2DM were 
divided randomly into two groups of vitamin E (400 mg/d, n=42) and placebo (n=41). All pa-
tients received the pearls for 8 weeks. Baseline and eighth week BP, serum hs-CRP, fasting blood 
glucose, anthropometric and dietary intake data were obtained from each patient. Data were ana-
lyzed using SPSS version 11.5.   
Results:  Vitamin  E  supplementation  significantly  increased  serum  levels  of  vitamin  E  (P  < 
0.001) and decreased mean arterial pressure and fasting blood glucose (P = 0.047, P = 0.028, re-
spectively) in vitamin E group as compared with placebo group. A significant decrease in systolic 
blood pressure and diastolic blood pressure was observed in the vitamin E group comparing with 
baseline values (all P < 0.01). There were no significant changes in serum hs-CRP in both of the 
studied groups.  
Conclusion: Vitamin E had beneficial effects on serum vitamin E, BP and blood glucose in pa-
tients with T2DM. Improvement in BP and glucose control may contribute to reducing compli-
cations of diabetes including cardiovascular risk in these patients.  
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Introduction 
 
Type 2 diabetes mellitus (T2DM) and 
cardiovascular  disease  (CVD),  as  non-
communicable diseases, are the main public 
health  challenge  for  the  21st  century  [1]. 
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T2DM  or  non-insulin-dependent  diabetes 
mellitus is a chronic disease characterized by 
hyperglycemia and insulin resistance [2]. The 
prevalence of type 2 diabetes is increasing at 
an alarming rate. The number of people with 
diabetes  worldwide  is  expected  to  rise  to 
well over 366 million by 2030 [3]. Changes 
in human behavior and lifestyle such as nu-
tritional  habits  over  the  last  century  have 
resulted in a dramatic increase in the inci-
dence of diabetes worldwide [1].  
Patients  with  type  2  diabetes  have  a 
significantly higher risk of developing coro-
nary heart disease and atherosclerosis. Poss-
ible reasons for accelerated atherosclerosis in 
these patients are oxidative stress, hyperten-
sion, and increased subclinical systemic in-
flammation [4-6]. Abnormally high levels of 
free radicals due to an over production or 
inadequate  removal  and  simultaneous  de-
cline in antioxidant defense mechanism can 
damage  cellular  proteins,  nucleic  acids  and 
membrane  lipids  [7].  It  is  noteworthy  that 
hyperglycemia induces reactive oxygen spe-
cies (ROS) generation [8]. The levels of ROS 
are  controlled  by  various  cellular  defense 
mechanisms  [9]. Vitamin  E  (α-tocopherol), 
the  well-known  scavenger  of  free  radicals, 
facilitates the reduction in ROS production 
and increases the antioxidant defense system 
[10]. Vitamin E is a lipid-soluble antioxidant 
found in virtually all cell membranes. This 
vitamin neutralizes free radicals, preventing 
the chain reaction that contributes to oxida-
tive damage [11].  
There has been an increasing interest 
in the involvement of low-grade inflamma-
tion (high-sensitivity C-reactive protein [hs-
CRP]) in the pathogenesis of type 2 diabetes. 
Hs-CRP  is  an  inflammatory  marker  with 
proinflammatory  and  proatherogenic  prop-
erties,  produced  and  released  by  the  liver 
under the stimulation of cytokines [12, 13]. 
Higher levels of hs-CRP in diabetic patients 
were showed in the previous studies [14, 15]. 
Elevated hs-CRP levels may predict CVD as 
well as the development of diabetes mellitus 
[16]. 
Several studies have reported that se-
rum  vitamin  E  is  lower  in  type  2  diabetic 
patients compared to healthy people [2, 17-
19]. It is postulated that vitamin E has bene-
ficial  effects  on  metabolic  control  of  di-
abetes  and  delays  the  long-term  complica-
tions of diabetes including CVD [10, 20].  
Low  dietary  intakes  and  plasma  con-
centrations  of  antioxidants  are  associated 
with  enhanced  risk  of  hypertension  [6]. 
However,  the  results  of  clinical  studies  on 
the effects of vitamin E supplementation on 
blood pressure (BP) are inconclusive [21-24].  
Since  we  did  not  find  any  published 
data about the effect of sole vitamin E sup-
plementation on BP in type 2 diabetic pa-
tients  and  the  scanty  and  conflicting  data 
about the impact of vitamin E on inflamma-
tion in these patients, we aimed to evaluate 
the effects of oral vitamin E supplementa-
tion on BP, serum hs-CRP and fasting blood 
glucose in type 2 diabetic patients.  
 
Materials and Methods 
 
This double-blinded, randomized, con-
trolled  clinical  trial  was  approved  by  the 
Ethics  Committee  of  Tabriz  University  of 
Medical Sciences and was registered on the 
Iranian  Registry  of  Clinical  Trials  website 
(available  at:  http://  www.irct.ir,  identifier: 
IRCT138904263664N2).  Written  informed 
consent was obtained from all studied sub-
jects.  
Eighty-four  type  2  diabetic  patients 
aged 30 to 60 years with a body mass index 
(BMI) lower than 35 kg/m
2 were recruited 
for this study from the Endocrinology Clin-
ic, Sina Hospital in Tabriz, Iran. Diagnosis 
of T2DM was assessed at least 1 year prior 
to  our  examination.  Exclusion  criteria  in-
cluded insulin treatment, smoking, nutrition-
al supplements intake or consumption dur-
ing 3 months before the study, use of estro-
gen, progesterone, diuretics, β-blockers and 
non-steroidal anti-inflammatory drugs, pres-
ence  of  renal,  liver,  heart,  thyroid  and  in-
flammatory  disorders,  and  pregnancy  or 
breast-feeding.  
The patients were randomized into two 
groups matched for sex, age, and BMI. The 
vitamin  E  group  (n  =  42)  received  400 Health Promotion Perspectives, Vol. 2, No. 1, 2012; P: 72-79 
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IU/day  of  vitamin  E  (400  mg  of  dl-  α-
tocopheryl acetate) and the control group (n 
=  42)  received  placebo  for  8  weeks.  Both 
vitamin E and placebo pearls were supplied 
by Zahravi Pharmacutical Company, Tehran, 
Iran. The vitamin E supplement and placebo 
had  an  identical  appearance.  The  partici-
pants were asked to continue their routine 
dietary intake and lifestyle and to avoid any 
changes in medication, if possible.  
Information  on  anthropometric  mea-
surements and dietary intakes, were collected 
by  trained  personnel  at  the  beginning  and 
end  of  the  trial.  Weight  and  height  were 
measured to the nearest 0.5 kg and 0.1 cm, 
respectively. BMI was calculated by dividing 
body weight (kilograms)  by height squared 
(meters). Dietary intakes during 3 days (in-
cluding  2-week  days  and  1  weekend)  were 
estimated using a 24-h dietary recall and ana-
lyzed by Nutritionist 4 software.  
The systolic and diastolic blood pres-
sure (SBP and DBP) (5 minutes seated rest, 
mean of two readings) were measured with a 
mercury sphygmomanometer at baseline and 
after 8 weeks of supplementation. Mean ar-
terial  pressure  (MAP)  was  calculated  using 
following formula: (SBP+2DBP)/3 [6]. 
 
Blood Ssampling 
Venous  blood  samples  (10  ml)  were 
obtained from patients at the beginning and 
at the end of the trial. Samples were taken 
after 12 h fasting period and before taking 
any  oral  hypoglycemic  agents  (OHAs).  Se-
rum  was  separated  from  whole  blood  by 
centrifugation.  Fasting  blood  glucose  assay 
was conducted on the same day, which sam-
ples were collected and other serum aliquots 
were frozen immediately at -70˚C until the 
assay.  
 
Biochemical Assays 
Serum concentrations of α-tocopherol 
were determined by high-performance liquid 
chromatography (HPLC) with UV detection 
(CE1200, High performance variable wave-
length monitor) according to the method of 
Karpinska et al. [25]. Briefly, plasma proteins 
were precipitated with methanol and lipids 
extracted with n-hexane. After evaporation, 
dry residue was dissolved with mobile phase 
(methanol) and mixed and then this solution 
was injected into a guard-column (ACE 3µm 
C18 column (4.6×100 mm): ACE-111-1046). 
Samples  were  run  at  a  flow  rate  of  1.0 
ml/min on a HPLC system (Cecil 1100 se-
ries, Cambridge, England). Absorption was 
monitored  at  292  nm  for  α-tocopherol. 
Concentrations  were  calculated  from  areas 
under the curve using an external calibration 
curve.  
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Fig.  1:  (a)  Chromatogram  of  α-tocopherol 
standard at 292 nm; 
(b) chromatogram of serum at 292 nm. Peak 
1: α-tocopherol  
 
 
Serum  hs-CRP  level  was  determined 
using  the  immunoturbidometric  method 
with a Parsazmun kit (Karaj, Iran).  
Fasting  blood  glucose  was  measured 
using  the  standard  enzymatic  methods  by 
Parsazmun kit (Karaj, Iran) by an autoana-
lyzer (Abbott Model Alcyon 300, USA).  Maryam Rafraf et al.: Impact of Vitamin E Supplementation … 
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Statistical Aanalysis  
Data were analyzed using SPSS version 
11.5.  The  normal  distribution  of  variables 
was tested and confirmed by Kolmogorov-
Smirnov test. For the hs-CRP and SBP that 
did not follow normal distribution, analyses 
were  performed  after  log  transformation. 
The  background  characteristics  and  dietary 
intakes of patients in the two groups were 
compared using independent samples t-test 
and chi-square test for quantitative and qua-
litative  variables,  respectively.  Differences 
between the two groups after the interven-
tion  were  determined  by  analysis  of  cova-
riance, adjusting for baseline measurements 
and  potential  confounders  (duration  of  di-
abetes  and  dietary  vitamin  E  intake).  The 
changes in biochemical and anthropometric 
measurements and dietary intakes of the pa-
tients between the beginning and the end of 
the trial were compared by paired-samples t 
test  in  each  group.  Results  with  P  <  0.05 
were considered as statistically significant. 
 
Results 
 
One patient was excluded from the sta-
tistical analysis because he changed his me-
dication during the trial. Baseline and anth-
ropometric  characteristics  and  dietary  vita-
min E intakes of the patients in the study 
groups are shown in Table 1. The initial cha-
racteristics were similar in the vitamin E and 
placebo groups (P > 0.05). There were no 
significant changes in BMI and dietary vita-
min E intake during the study period (data 
not  shown).  Results  of  24-h  dietary  recall 
showed no significant differences in the in-
takes of energy and macronutrients between 
the  two  groups  at  baseline  and  during  the 
trial period (data not shown). 
There  were  no  significant  differences 
between groups by independent samples t-
test or χ
2-test (all P > 0.05). 
At  the  beginning  of  the  study,  the 
groups were similar based upon serum levels 
of vitamin E, SBP, DBP, MAP, hs-CRP and 
blood  glucose  (Table  2). After  8 weeks  of 
supplementation, serum levels of vitamin E 
increased significantly (P < 0.001) and MAP 
and fasting blood glucose decreased signifi-
cantly (P = 0.047, P = 0.047, respectively) in 
vitamin  E  group  compared  with  placebo 
group.  Following  intervention,  SBP,  DBP 
and MAP decreased significantly in vitamin 
E group comparing to baseline values (all P 
<  0.01).  We  did  not  find  any  significant 
changes  in  serum  hs-CRP  in  both  of  the 
studied groups (P > 0.05).  
   
 
 
Table 1: Baseline characteristics of the studied subjects 
 
Variables  Placebo group 
(n=41) 
Vitamin E group 
(n=42) 
Age (yr)  35.49 ± 8.02  35.10 ± 6.93 
Male/female (n)  14/27  15/27 
Weight (kg)  74.94 ± 9.53  74.76 ± 11.35 
BMI (kg/m
2)  29.88 ± 3.63  28.54 ± 3.57 
Duration of diabetes (years)  6.76 ± 5.77  6.28 ± 5.19 
Duration of OHAs treatment (years)  5.57 ± 5.05  4.32 ± 4.20 
Dietary vitamin E intake (mg/d)  4.74 ± 2.78  4.76 ± 2.52 
BMI: body mass index; OHAs: oral hypoglycemic agents  
The results are expressed as the mean ± SD 
 
 
 
Table 2: Mean ± SEM of vitamin E, SBP, DBP, MAP, hs-CRP and glucose in type 2 diabetic 
patients at baseline and the eighth week of study  Health Promotion Perspectives, Vol. 2, No. 1, 2012; P: 72-79 
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Variables 
Placebo group  
(n=41) 
  Vitamin E group  
(n=42) 
Baseline  After  
intervention 
P ‡    Baseline  After  inter-
vention 
P ‡ 
Serum vitamin E (mg/L)*  3.14 ± 0.10  3.11 ± 0.13  NS    3.11 ± 0.13  6.30 ± 0.26  <0.001 
SBP (mmHg)  134.38 ± 3.01  132.88 ± 3.32  NS    137.25 ± 5.02  127.38 ± 3.47  <0.01 
DBP (mmHg)  81.38 ± 1.33  78.88 ± 1.64  NS    83.25 ± 2.28  75.88 ± 2.09   <0.01 
MAP (mmHg) †  99.04 ± 1.77  96.88 ± 1.98  NS    101.25 ± 3.10  93.04 ± 2.37   <0.01 
Serum hs-CRP (mg/L)  1.43 ± 0.19  1.50 ± 0.20  NS    1.24 ± 0.14  1.21 ± 0.15  NS 
Blood glucose (mg/dL) †  120.18 ± 4.93  124.70 ± 4.61  NS    128.13 ± 5.33  119.03 ± 3.47   <0.05 
SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: Mean arterial pressure; hs-CRP: high-sensitivity 
C-reactive protein; NS: Non-significant.  
* Significant differences between groups after intervention using analysis of covariance (adjusted for duration of di-
abetes, vitamin E intake, and baseline values): P < 0.001 
† Significant differences between groups after intervention using analysis of covariance (adjusted for duration of di-
abetes, vitamin E intake, and baseline values): P < 0.05 
‡ using paired samples t-test 
 
Discussion 
 
This study (Table 1) showed that daily 
dietary intake of vitamin E in all of partici-
pants  was  lower  than  dietary  reference  in-
takes (15 mg/day) [26]. At the beginning of 
the study (Table 2), subjects in both groups 
had vitamin E serum levels lower than the 
reference  range  (5.7-20  mg/L)  [27].  After 
supplementation,  significant  increase  in  se-
rum vitamin E level was observed in vitamin 
E group. Lower serum vitamin E levels were 
previously  observed  in  type  2  diabetic  pa-
tients [2, 17-19].  
Cardiovascular  complications  are  the 
most common cause of high mortality rate 
in  type  2  diabetes.  Hypertension  and  in-
flammation  are  contributory  factors  that 
promote the development of complications 
[6, 15]. The SHEP study (the Systolic Hyper-
tension in the Elderly Program) has clearly 
shown twice the absolute risk reduction in 
cardiovascular  events  following  tight  BP 
control  in  type  2  diabetic  subjects  than  in 
non-diabetics [28]. Data from the UKPDS 
(UK  Prospective  Diabetes  Study  Group) 
showed that BP control in a cohort of newly 
diagnosed subjects with type 2 diabetes was 
effective in reducing microvascular compli-
cations [29], and BP reduction would slow 
the  progression  of  diabetic  nephropathy 
[30].  
Our data (Table 2), indicated that vi-
tamin E significantly decreased MAP in the 
vitamin E group comparing with the control 
group  and  reduced  SBP  and  DBP  in  this 
group in comparison to the baseline values. 
It had been shown that  BP is sensitive to 
alteration of weight and dietary intakes [6], 
but  these  variables  did  not  change  in  our 
studied  groups.  Therefore,  the  observed 
findings  after  intervention  could  not  have 
been caused by the alterations in weight and 
dietary intakes. Several studies confirmed the 
results of the present study. Vitamin E in the 
long  term  can  reduce  BP  in  patients  with 
mild hypertension [21]. Its supplementation 
can  improve  BP  status  in  rats  [24].  En-
hancement of antioxidant status by supple-
mentation with vitamins C and E in patients 
with essential hypertension is associated with 
decreased BP [31].  
Several  data  indicate  that  intracellular 
magnesium may play a key role in modulat-
ing vascular tone and hypertension [32]. It is 
proposed that increased oxygen free radical 
production lowers the intracellular Mg con-
centration,  and,  in  light  of  such  evidence, 
vitamin  E  administration  may  regulate  the 
intracellular  Mg  concentration  [6].  In  this 
way,  vitamin  E  supplementation  may  in-
crease intracellular magnesium and therefore Maryam Rafraf et al.: Impact of Vitamin E Supplementation … 
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decrease BP. Our findings confirm the anti-
hypertensive properties of vitamin E. There-
fore, vitamin E may have a potential benefi-
cial effect regarding CVD.  
CRP  is  a  risk  factor  for  CVD  and  it 
could contribute to atherosclerosis [33]. Vi-
tamin  E  therapy,  especially  at  high  doses, 
has been shown to decrease release of pro-
inflammatory  cytokines  (including  interleu-
kin-1beta, interleukin-6, and tumor necrosis 
factor-alpha),  and  inflammatory  markers 
such as CRP, and to decrease adhesion of 
monocytes  to  endothelium  [4,  34].  High 
dose  of  vitamin  E  supplementation  (1200 
IU/day)  significantly  lowered  the  levels  of 
hs-CRP in type 2 diabetic patients with high 
baseline  levels  of  hs-CRP  [15].  In  the 
present  study,  400  mg/day  vitamin  E  did 
not  have  any  effect  on  serum  hs-CRP  in 
type 2 diabetic patients (Table 2). Our find-
ings are similar to the result obtained by Wu 
et al. in a trial with 500 mg/day α-tocopherol 
for 6 weeks on patients with T2DM [5].  
CRP levels are categorized for risk as 
low (<1 mg/L); average (2 to 3 mg/L) and 
high (>3 mg/L) [35]. The baseline value of 
hs-CRP in all of our patients was lower than 
2 mg/L. No significant change of serum hs-
CRP by vitamin E in this study may be due 
to  lower  baseline  levels  of  hs-CRP  in  our 
patients  or  insufficient  dose  of  vitamin  E 
supplement.  Other  studies  are  needed  to 
evaluate  the  impact  of  vitamin  E  supple-
ments on other inflammatory parameters in 
type 2 diabetic patients.  
We  observed  that  the  serum  level  of 
fasting  blood  glucose  was  significantly  re-
duced  after  vitamin  E  supplementation  in 
the intervention group as compared with the 
placebo  group  (Table  2).  This  result  is  in 
agreement  with  some  previous  reports  on 
type 2 diabetic patients [36, 37]. Paolisso et 
al. reported an improvement in fasting blood 
glucose after 900 IU/day vitamin E supple-
mentation during 3 months [36]. Similar re-
sult was observed after 800 IU/day supple-
mentation  of vitamin E for  one  month  in 
these patients [37]. It is suggested that vita-
min E can be effective in inhibiting hyper-
glycemia by scavenging ROS [10]. However, 
some studies did not show any changes in 
fasting blood glucose after intervention with 
vitamin E on patients with T2DM [17, 20, 
38]. Part of this discrepancy can be due to 
differences in the duration of the interven-
tion, studied subjects, or dose of vitamin E 
supplements. 
 
Conclusion 
 
This  study demonstrated that vitamin 
E had beneficial effects on serum vitamin E, 
BP and blood glucose in type 2 diabetic pa-
tients. Improvement in BP and glucose con-
trol may contribute to reducing cardiovascu-
lar risk or complications of diabetes in these 
patients.  
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